Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drug Discovery: Overview01:26

Drug Discovery: Overview

7.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.9K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

729
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
729
Quantitative Aspects of Drug-Receptor Interaction01:30

Quantitative Aspects of Drug-Receptor Interaction

999
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
999
Drug-Receptor Bonds01:25

Drug-Receptor Bonds

2.9K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
2.9K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

2.5K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.5K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

3.0K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
3.0K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

African digital health strategic plans analysis: key weaknesses in contextualization, intervention focus, and technological foresight.

NPJ digital medicine·2025
Same author

User journeys in cross-European secondary use of health data: insights ahead of the European Health Data Space.

European journal of public health·2025
Same author

Optimizing Global Network Alignment With a Genetic Algorithm: Leveraging Pre-Trained Embeddings for Protein Sequences and Gene Ontology Terms.

IEEE transactions on computational biology and bioinformatics·2025
Same author

scEVE: a single-cell RNA-seq ensemble clustering algorithm capitalizing on the differences of predictions between multiple clustering methods.

NAR genomics and bioinformatics·2025
Same author

25 Years of Digital Health Toward Universal Health Coverage in Low- and Middle-Income Countries: Rapid Systematic Review.

Journal of medical Internet research·2025
Same author

Integrating Health Care Data in an Informatics for Integrating Biology & the Bedside (i2b2) Model Persisted Through Elasticsearch: Design, Implementation, and Evaluation in a French University Hospital.

JMIR medical informatics·2025

相关实验视频

Updated: Jul 9, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K

关于计算药物重新利用的OREGANO知识图.

Marina Boudin1, Gayo Diallo2, Martin Drancé2

  • 1AHeaD team, Bordeaux Population Health Inserm U1219, Univ. Bordeaux, F-33000, Bordeaux, France. marina.boudin@u-bordeaux.fr.

Scientific data
|December 6, 2023
PubMed
概括

奥里加诺知识图为计算药物重新定位提供了一个免费可用的资源. 它整合了各种药物和天然化合物数据,通过链接预测加速药物发现.

科学领域:

  • 计算生物学是一种计算生物学.
  • 药理学 药理学是指药理学的学科.
  • 生物信息学是一种生物信息学.

背景情况:

  • 与传统方法相比,药物重新定位加速了药物发现.
  • 使用知识图的计算方法显示出产生药物标假设的前景.
  • 缺乏一个全面的,社区可访问的知识图,整合广泛的药物特征.

研究的目的:

  • 介绍OREGANO知识图,这是一个用于药物重新定位的新型资源.
  • 将自然化合物数据纳入一个全面的知识图.
  • 提供对知识图及其相关ETL源代码的开放访问.

主要方法:

  • 通过整合来自多个来源的数据,从头开始开发了一个知识图.
  • 为数据集成设计了一个图形模型和一个节点合并策略.
  • 实现了一个提取,转换,加载 (ETL) 过程与数据清理.

主要成果:

  • 成功构建了OREGANO知识图,包括自然化合物数据.
  • 知识图和ETL源代码在GitHub上公开提供.
  • 该资源通过链接预测促进了对药物重新定位的假设生成.

更多相关视频

A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports
07:35

A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports

Published on: October 13, 2023

1.7K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.2K

相关实验视频

Last Updated: Jul 9, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K
A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports
07:35

A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports

Published on: October 13, 2023

1.7K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.2K

结论:

  • 奥里加诺解决了对药物重新定位的整体,社区可访问的知识图的需求.
  • 集成的数据和OREGANO的开源性质可以推动计算药物发现.
  • 该资源支持更快,更实惠的药物开发管道.